2 Tiny Stocks That Should Be This Week's Biggest Movers

For beginning investors, it's often difficult to tell the difference between solid, long-term decisions and dumb, short-term luck. When a stock you own makes huge moves -- up or down -- in a single day, it's easy to let emotions run wild and make a buy/sell decision that you'll end up regretting.

If you own shares in either Galena Biopharma Inc. (NASDAQ: GALE  ) or ExOne Co. (NASDAQ: XONE  ) , three forces are combining to create such moves this week. The first is that both are small companies, each worth less than $1 billion. The second is that each is reporting earnings, and Wall Street watches extra closely when this happens. And the final factor is that a lot of investors are shorting -- or betting against the success of -- each company's stock.

To make sure you're prepared for the week ahead, here's what to look out for:

Company

% of Shares Short

When?

Expected Revenue (Millions)

Expected EPS

Galena Biopharma Inc.

21%

Tuesday

$1.6

($0.09)

ExOne Co.

33%

Thursday

$12.1

$0.01

Sources: finviz.com, E*Trade.

Galena Biopharma Inc.
Though Galena already has one medication -- for relieving cancer pain -- approved by the FDA, the company's future rests squarely on the success of its NeuVax line of breast and gastric cancer drugs. The former is already in phase 3 trials, while the latter is just beginning phase 2 testing.

Investors in the company have endured quite the roller-coaster ride. Between November and January, the company's stock rose almost 250%. The first catalyst was an announcement of successful early-stage trials for a drug targeted at preventing ovarian and endometrial cancer relapses. Several institutional investors started buying shares shortly thereafter, and then Galena announced they were acquiring Mills Pharmaceuticals. These events combined to create a snowball effect, sending the stock soaring.

But the market hasn't been so kind to shareholders since then. Shares have lost more than half of their value, in part because the company was alleged to have paid a firm to pump up Galena's potential.

When Galena reports this week, meeting revenue expectations won't be nearly as important as listening to the company's conference call. Of course, there may be questions about the stock-pump allegations. Some earlier-stage treatments may report positive developments. But investors should remain squarely focused on any progress coming from the company's line of NeuVax treatments.

ExOne

Sources: ExOne.

The preceding images paint a picture for the diverse number of objects that can be printed in glass, sand, or metal using ExOne's industrial 3-D printers. Though the company has brought in a scant $42 million in revenue over the past year while losing $0.26 per share -- versus a $600 million valuation -- investors think there's lots of reason to get excited about ExOne's potential.

For starters, the company is squarely focused on the industrial sector. Although these customers usually take longer to win over, in the end, they're usually far more lucrative than commercial or consumer users. ExOne's only real competition -- focused solely on the industrial sector -- is voxeljet (NYSE: VJET  ) , a German company that has already earned the ire of some investors for foolishly overspending and misallocating some of the proceeds from its recent IPO.

That being said, ExOne shareholders have had to endure a tough year so far, with shares trading down about 35% from early January highs. That's largely because the company announced that a few key customers put off their purchases until the first quarter of 2014 began. Investors should listen in to make sure these purchases were, in fact, made by now, and what the company sees in terms of sales for the rest of the year.

A less nerve-wracking way to get your financial independence
It's no secret that investors tend to be impatient with the market, but the best investment strategy is to buy shares in solid businesses and keep them for the long term. In the special free report "3 Stocks That Will Help You Retire Rich," The Motley Fool shares investment ideas and strategies that could help you build wealth for years to come. Click here to grab your free copy today.


Read/Post Comments (5) | Recommend This Article (13)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 16, 2014, at 1:55 PM, Protocola wrote:

    Dear Brian,

    >>stock you own makes huge moves -- up or down -- in a single day<<

    "Biggest Movers" as in UPward move or DOWNward move?

    Can you be any more ambiguous or are you in CYA mode? This is the reason why so few click on/read these 'pearls of wisdom' much less leave a comment.

  • Report this Comment On March 16, 2014, at 2:28 PM, TMFCheesehead wrote:

    @protocola-

    Predicting which way they might move would be a very unwise thing to do. There's no way anyone can know this unless they have insider information of what the company will say.

    Instead, the article serves as a heads-up to shareholders to prepare themselves for big moves, and ensure they take a minute and breathe before making any buy/sell decisions.

    Brian Stoffel

  • Report this Comment On March 17, 2014, at 3:14 AM, Bafi008 wrote:

    May I ask:

    If "investors should remain squarely focused on any progress coming from the company's line of NeuVax treatments" then why an income of $2M-$3M would make any difference? IMHO this year there will be no material results regarding NeuVax. What am I missing?

  • Report this Comment On March 17, 2014, at 10:53 AM, Angelstar wrote:

    Buy Ariad pharmaceuticals.... Takeover bid announcement coming....

  • Report this Comment On March 17, 2014, at 11:31 AM, TMFCheesehead wrote:

    @Bafi008-

    The revenue numbers are just standard ones I include to give an idea of what Wall Street is looking for.

    I should have made it clearer that investors should listen in on the conference call, the question and answer session on the CC, and any statements in the press release regarding NeuVax.

    Brian Stoffel

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2873237, ~/Articles/ArticleHandler.aspx, 10/24/2014 2:56:07 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement